{"altmetric_id":6002354,"counts":{"readers":{"mendeley":10,"citeulike":0,"connotea":0},"total":{"posts_count":4},"twitter":{"unique_users_count":4,"unique_users":["Medinteract","GrupoPKgen_SEFH","laida_ep","GarbineLizeaga"],"posts_count":4}},"selected_quotes":["Drug-Drug #Interactions: #CHV #Ombitasvir, #Paritaprevir\/Ritonavir, #Dasabuvir and Eight Commonly Used Medications htt\u2026","Drug-Drug #Interactions: #CHV #Ombitasvir, #Paritaprevir\/Ritonavir, #Dasabuvir and Eight Commonly Used Medications","Alerta si se utiliza diazepam, ciclobenzaprina o hidroxicodona con ombitasvir, paritaprevir, ritonavir y dasabuvir."],"citation":{"abstract":"The three direct-acting antiviral regimen of ombitasvir\/paritaprevir\/ritonavir and dasabuvir (3D regimen) is approved for treatment of hepatitis\u00a0C virus (HCV) genotype\u00a01 infection. Drug-drug interaction (DDI) studies of the 3D regimen and commonly used medications were conducted in healthy volunteers to provide information on coadministering these medications with or without dose adjustments.\nThree phase\u00a0I studies evaluated DDIs between the 3D regimen (ombitasvir\/paritaprevir\/ritonavir 25\/150\/100\u00a0mg once daily\u00a0+\u00a0dasabuvir 250\u00a0mg twice daily) and hydrocodone bitartrate\/acetaminophen (5\/300\u00a0mg), metformin hydrochloride (500\u00a0mg), diazepam (2\u00a0mg), cyclobenzaprine hydrochloride (5\u00a0mg), carisoprodol (250\u00a0mg), or sulfamethoxazole\/trimethoprim (SMZ\/TMP) (800\/160\u00a0mg twice daily), all administered orally. DDI magnitude was determined using geometric mean ratios and 90\u00a0% confidence intervals for the maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC).\nChanges in exposures (C max and AUC geometric mean ratios) of acetaminophen, metformin, sulfamethoxazole, trimethoprim, and diazepam were \u226425\u00a0% upon coadministration with the 3D regimen. The C max and AUC of nordiazepam, an active metabolite of diazepam, increased by 10\u00a0% and decreased by 44\u00a0%, respectively. Exposures of cyclobenzaprine and carisoprodol decreased by \u226440 and \u226446\u00a0%, respectively, whereas exposures of hydrocodone increased up to 90\u00a0%. Ombitasvir, paritaprevir, ritonavir, and dasabuvir exposures changed by \u226425\u00a0%, except for a 37\u00a0% decrease in paritaprevir C max with metformin and a 33\u00a0% increase in dasabuvir AUC with SMZ\/TMP.\nAcetaminophen, metformin, sulfamethoxazole, and trimethoprim can be coadministered with the 3D regimen without dose adjustment. Higher doses may be needed for diazepam, cyclobenzaprine, and carisoprodol based on clinical monitoring. A 50\u00a0% lower dose and\/or clinical monitoring should be considered for hydrocodone. No dose adjustment is necessary for the 3D regimen.","altmetric_jid":"4f6fa4ea3cf058f610002571","authors":["Akshanth R. Polepally","Jennifer R. King","Bifeng Ding","Diana L. Shuster","Emily O. Dumas","Amit Khatri","Yi-Lin Chiu","Thomas J. Podsadecki","Rajeev M. Menon"],"doi":"10.1007\/s40262-016-0373-8","first_seen_on":"2016-02-25T09:00:58+00:00","funders":["niehs"],"issns":["0312-5963","1179-1926"],"journal":"Clinical Pharmacokinetics","last_mentioned_on":1456816061,"links":["http:\/\/link.springer.com\/article\/10.1007\/s40262-016-0373-8"],"pdf_url":"http:\/\/link.springer.com\/content\/pdf\/10.1007%2Fs40262-016-0373-8.pdf","pmid":"26895022","pubdate":"2016-02-19T00:00:00+00:00","publisher":"Springer International Publishing","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"},{"name":"Internal Medicine","scheme":"springer"},{"name":"Medicine & Public Health","scheme":"springer"},{"name":"Pharmacology\/Toxicology","scheme":"springer"},{"name":"Pharmacotherapy","scheme":"springer"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Pharmacology, Toxicology and Pharmaceutics"],"subjects":["pharmacology"],"title":"Drug\u2013Drug Interactions Between the Anti-Hepatitis\u00a0C Virus 3D Regimen of Ombitasvir, Paritaprevir\/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/drugdrug-interactions-between-antihepatitisc-virus-3d-regimen-ombitasvir-paritaprevirritonavir-dasab"},"altmetric_score":{"score":1.75,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":1.75},"context_for_score":{"all":{"total_number_of_other_articles":7325869,"mean":6.3768565404091,"rank":3210021,"this_scored_higher_than_pct":55,"this_scored_higher_than":4044050,"rank_type":"exact","sample_size":7325869,"percentile":55},"similar_age_3m":{"total_number_of_other_articles":282683,"mean":10.458441379359,"rank":120859,"this_scored_higher_than_pct":55,"this_scored_higher_than":157048,"rank_type":"exact","sample_size":282683,"percentile":55},"this_journal":{"total_number_of_other_articles":584,"mean":3.1690120068611,"rank":356,"this_scored_higher_than_pct":38,"this_scored_higher_than":223,"rank_type":"exact","sample_size":584,"percentile":38},"similar_age_this_journal_3m":{"total_number_of_other_articles":17,"mean":5.730625,"rank":9,"this_scored_higher_than_pct":41,"this_scored_higher_than":7,"rank_type":"exact","sample_size":17,"percentile":41}}},"demographics":{"poster_types":{"member_of_the_public":4},"users":{"twitter":{"cohorts":{"Members of the public":4}},"mendeley":{"by_status":{"Librarian":1,"Student  > Ph. D. Student":1,"Student  > Postgraduate":1,"Other":2,"Student  > Master":2,"Student  > Bachelor":2,"Professor":1},"by_discipline":{"Medicine and Dentistry":8,"Unspecified":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"twitter":{"ES":3}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/Medinteract\/statuses\/702777963788500992","license":"gnip","citation_ids":[6002354],"posted_on":"2016-02-25T08:51:38+00:00","author":{"name":"Medinteract","url":"http:\/\/www.medinteract.net\/","image":"https:\/\/pbs.twimg.com\/profile_images\/553115165399330816\/FeYZOdg-_normal.jpeg","description":"Por el conocimiento de las Interacciones Farmacol\u00f3gicas","id_on_source":"Medinteract","tweeter_id":"300138428","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":724},"tweet_id":"702777963788500992"},{"url":"http:\/\/twitter.com\/GrupoPKgen_SEFH\/statuses\/704302767096111106","license":"gnip","citation_ids":[6002354],"posted_on":"2016-02-29T13:50:39+00:00","author":{"name":"Grupo PK.gen SEFH","url":"http:\/\/www.sefh.es","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000632170332\/651d4316065a89aa7167d3435dcf039d_normal.jpeg","description":"Grupo de Farmacocin\u00e9tica Cl\u00ednica y Farmacogen\u00e9tica de la Sociedad Espa\u00f1ola de Farmacia Hospitalaria.","id_on_source":"GrupoPKgen_SEFH","tweeter_id":"1963301778","geo":{"lt":40,"ln":-4,"country":"ES"},"followers":1280},"tweet_id":"704302767096111106"},{"url":"http:\/\/twitter.com\/laida_ep\/statuses\/704562813319168000","license":"gnip","rt":["GrupoPKgen_SEFH"],"citation_ids":[6002354],"posted_on":"2016-03-01T07:03:59+00:00","author":{"name":"Laida Elberd\u00edn Pazos","url":"https:\/\/www.linkedin.com\/profile\/view?id=288209620","image":"https:\/\/pbs.twimg.com\/profile_images\/544144004166602752\/YYSkVrRZ_normal.jpeg","description":"Farmac\u00e9utica Especialista en Farmacia Hospitalaria. Miembro Grupo PK.gen SEFH. \n          En @FarmaCHUAC en consulta de Derma y monitorizando biol\u00f3gicos","id_on_source":"laida_ep","tweeter_id":"2183013260","geo":{"lt":43.37135,"ln":-8.396,"country":"ES"},"followers":248},"tweet_id":"704562813319168000"},{"url":"http:\/\/twitter.com\/GarbineLizeaga\/statuses\/704563743783591936","license":"gnip","rt":["GrupoPKgen_SEFH"],"citation_ids":[6002354],"posted_on":"2016-03-01T07:07:41+00:00","author":{"name":"Garbi\u00f1e Lizeaga","image":"https:\/\/pbs.twimg.com\/profile_images\/786651537573572608\/fOvQvTXd_normal.jpg","description":"FHyAP. OSI Donostialdea. De todo como en botica.","id_on_source":"GarbineLizeaga","tweeter_id":"2244183212","geo":{"lt":null,"ln":null},"followers":401},"tweet_id":"704563743783591936"}]}}